Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376915 | 0.89 | SMN1; SMN2 (0.43) | METAP2EGFRHTTSMN1; SMN2KDM4E | |
| SCHEMBL5372437 | 0.88 | METAP2 (0.52) | METAP2P2RX7MAPK1HTTSMN1; SMN2 | |
| SCHEMBL5376834 | 0.86 | METAP2 (0.67) | METAP2P2RX7SMN1; SMN2 | |
| SCHEMBL5373564 | 0.86 | GBA1 (0.50) | METAP2EGFRHTTSMN1; SMN2KDM4E | |
| SCHEMBL5387230 | 0.85 | MAPT (0.48) | METAP2EGFRSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5381456 | 0.84 | METAP2 (0.51) | METAP2P2RX7MAPK1SMN1; SMN2MAPT | |
| SCHEMBL5393520 | 0.84 | ALPL (0.53) | METAP2EGFRSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5381440 | 0.83 | METAP2 (0.50) | METAP2MAPK1 | |
| SCHEMBL5391914 | 0.83 | METAP2 (0.68) | METAP2MAPK1 | |
| SCHEMBL5385018 | 0.82 | METAP2 (0.48) | METAP2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223932-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| EP-1223932-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2001024796-A1 | 1,2,4-TRIAZOLE DERIVATIVES, COMPOSITION, PROCESS OF MAKING AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-12 | — | — | WO | claimed |
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
| EP-1223932-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1223932-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001024796-A1 | 1,2,4-TRIAZOLE DERIVATIVES, COMPOSITION, PROCESS OF MAKING AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | METAP2, METAP1, DNPEP | METAP2 1/4885P2RX7 3236/4885MAPK1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.